AstraZeneca PLC / Rigel Pharmaceuticals, Inc. (Fostamatinib license)

Rheumatoid Arthritis

Disease Overview

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease causing synovial inflammation, joint destruction, and disability. It disproportionately affects women, typically presents in mid-adulthood, and despite widespread use of methotrexate and biologics, a substantial subset of patients fail or cycle through TNF and other targeted therapies — fueling demand for novel oral mechanisms.

Competitive Landscape

In early 2010, RA treatment was dominated by methotrexate as anchor therapy plus injectable TNF inhibitors — Humira (adalimumab, AbbVie), Enbrel (etanercept, Amgen/Pfizer), and Remicade (infliximab, J&J/Merck) — collectively a multi-billion-dollar franchise. Roche/Genentech's Rituxan and Actemra plus Bristol's Orencia served TNF failures. The unmet need at the time was a convenient oral disease-modifying option; Pfizer's Xeljanz (tofacitinib, JAK inhibitor) was advancing in Phase 3 and would be approved in 2012 as the first oral targeted DMARD. Fostamatinib was the most clinically advanced oral Spleen Tyrosine Kinase (Syk) inhibitor and represented a differentiated mechanism intended to compete in the oral DMARD opening alongside JAK inhibitors. The 2010 deal — $100M upfront plus up to $1.145B in milestones, royalties on net sales — was named Scrip's Licensing Deal of the Year. However, the OSKIRA Phase 3 program produced disappointing results in 2013; AstraZeneca returned rights to Rigel that year. Fostamatinib was ultimately approved as Tavalisse for chronic immune thrombocytopenia in 2018 — not RA. (Source: https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-and-Rigel-Pharmaceuticals-Sign-Worldwide-License-Agreement-for-Late-Stage-Development-Product-Fostamatinib-Disodium-R788-for-the-Treatment-of-Rheumatoid-Arthritis-16022010.html)